tbuckley/cabot-search huggingface dataset:
Hyperkeratosis in Flegel's disease
Authors: V. Burmeister
Journal: JAMA (1985)

Hyperkeratosis lenticularis perstans was first described by Flegel<sup>1</sup>in 1958. It may rightly be redefined as an autosomal dominant mucocutaneous syndrome of variable expressivity, characterized by an aberration in the keratinization process. A 67-year-old woman presented with numerous asymptomatic keratotic lesions, confined to the anterior aspect of the legs and the dorsa of the feet. These skin-colored papules varied in size from 1 to 4 mm in diameter. Other manifestations were palmar pits and mucosal lesions on the tongue. The patient was treated with vitamin A (Aquasol A) and topical tretinoin 0.01% gel (Retin-A), with some response. The lack of patient compliance ruled out the use of isotretinoin (Accutane). A specimen from a skin biopsy was examined under a light microscope and displayed massive hyperkeratosis and spotty parakeratosis, with the granular layer being absent in most areas except in the relatively normal margin. There was some irregular acanthosis in
THE PUBLIC SERVICE.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Dose in Figure
Journal: JAMA (2015)

George L. Bakris, MD; Bertram Pitt, MD; Matthew R. Weir, MD; Mason W. Freeman, MD; Martha R. Mayo, PharmD; Dahlia Garza, MD; Yuri Stasiv, PhD; Rezi Zawadzki, DrPH; Lance Berman, MD; David A. Bushinsky, MD; for the AMETHYST-DN Investigators
Olympic dreams
Authors: D. MacAuley
Journal: BMJ (2008)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Olympic dreams Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
INTESTINAL PUTREFACTION.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hirsutism
Authors: ROGER S. RITTMASTER
Journal: Annals of Internal Medicine (1987)

Excess body hair, or hirsutism, is usually only a problem in women and can cause considerable psychological distress. The disorder is usually androgen mediated. Because androgens come only from the adrenal glands or gonads or by conversion in peripheral tissues of precursor steroids from these organs, the causes of hirsutism are found in these two organs. Adrenal causes include Cushing's disease, adrenal tumors, and congenital adrenal hyperplasia. Ovarian causes include tumors, polycystic ovarian syndrome, and most cases of idiopathic hirsutism. The clinical evaluation is designed to differentiate between these diagnostic possibilities. When an underlying abnormality can be identified, such as an ovarian tumor, the treatment course is clear. When the diagnosis is idiopathic hirsutism, however, the best treatment is uncertain and several available regimens are possible.
Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Authors: Jorge Cortes, Guillermo Garcia-Manero, Susan O’Brien, Srdan Verstovsek, Zeev Estrov, Francis Giles, Farhad Ravandi, John Wright, Hagop Kantarjian
Journal: Blood (2005)
Progress Toward Global Measles Control and Elimination, 1990-1996
Journal: JAMA (1997)

In 1989, the World Health Assembly resolved to reduce measles morbidity by 90% and measles mortality by 95% by 1995, compared with disease burden during the prevaccine era. By 1996, the estimated incidence and death rates for measles worldwide were reduced by 78% and 88%, respectively. In 1990, the World Summit for Children adopted a goal of vaccinating 90% of children against measles by 2000. However, routine measles vaccination coverage has remained relatively stable since 1990, and an estimated 1 million children continue to die from this preventable disease each year. During the 1990s, the widespread use of innovative measles-control strategies in the Region of the Americas and countries such as Mongolia, South Africa, and the United Kingdom demonstrated that high-level measles control and even interruption of transmission is feasible over large geographic areas. This report updates the status of measles control and elimination worldwide and includes disease surveillance and vaccination coverage data received by the World Health Organization (WHO) headquarters in Geneva, Switzerland, as of August 29, 1997. These findings indicate that, in some regions, substantial progress has been made to control and interrupt measles transmission; in others, measles continues to cause high morbidity and mortality because of failure to implement measles-control strategies.The World Health Assembly in 1989 resolved to reduce the levels of measles morbidity and mortality by 90% and 95%, respectively, by 1995. By 1996, the estimated incidence and death rates for measles worldwide had been reduced by 78% and 88%, respectively. In 1990, the World Summit for Children adopted the goal to vaccinate 90% of children against measles by 2000, but routine measles vaccination coverage has remained relatively stable since that year. Disease surveillance and vaccination coverage data received by the World Health Organization (WHO) headquarters as of August 29, 1997, indicate that in some regions, substantial progress has been made to control and interrupt measles transmission, while in others, measles continues to cause high morbidity and mortality because of failure to implement control strategies. The stages of measles control and progress toward implementing strategies are discussed. During 1980-96, the number of reported measles cases worldwide declined from 4.4 million to approximately 0.8 million. However, since measles reporting is incomplete, the actual burden from measles is estimated at 36.5 million cases and 1 million deaths. In 1996, 62% (445,949) of the measles cases worldwide were reported from the Africa Region. Of the 6 WHO regions, disease burden in 1996 was lowest in the Americas with only 2109 cases, of which 488 were reported from the US.
Body Heat Management in People Using Cocaine
Journal: Annals of Internal Medicine (2002)

Summaries for Patients4 June 2002Body Heat Management in People Using CocaineSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-11-200206040-00001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Cocaine abuse can kill people by increasing body temperature to fatal levels. In the past, doctors have assumed that increased body temperature was caused by the agitation and increased muscular activity that often accompany cocaine use. There are at least two ways the body gets rid of excess heat: behavioral methods (such as avoidance of hot rooms) and physiologic methods (such as sweating and increasing blood flow through vessels near the surface of the skin, as can be seen in the rosy cheeks of a running child). Since ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Mechanism of Cocaine-Induced Hyperthermia in Humans.” It is in the 4 June 2002 issue of Annals of Internal Medicine (volume 136, pages 785-791). The authors are CG Crandall, W Vongpatanasin, and RG Victor.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMechanism of Cocaine-Induced Hyperthermia in Humans Craig G. Crandall , Wanpen Vongpatanasin , and Ronald G. Victor Metrics 4 June 2002Volume 136, Issue 11Page: I-20KeywordsAnestheticsBlood flowCocaineHyperthermiaRunningSaline solutionsTemperatureThermometers ePublished: 4 June 2002 Issue Published: 4 June 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Ovarian Physiology
Authors: George S. Richardson
Journal: New England Journal of Medicine (1966)

Steroid Content of the OvaryShort,153 who studied the steroid content of the follicular fluid of mares at various stages in the reproductive cycle, as well as the corpus luteum of the same animal, found the follicle to contain progesterone, 17-hydroxyprogesterone, androstenedione, epitestosterone (but not testosterone), 19-norandrostenedione (a striking observation in view of the previous discussion), estrone, estradiol and 6α-hydroxyestradiol. No pregnenolone or 17-hydroxypregnenolone and very little dehydroepiandrosterone were noted, suggesting that the Δ5 pathway might be relatively unimportant in this phase of the cycle in this species. The corpus luteum contained chiefly progesterone, trailed by 20α-dihydroprogesterone, and a small . . .
THE REMOTE EFFECTS OF FŒTAL BRAIN INJURY IN LABOR; OR, WHY WE ARE RIGHT-HANDED.
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical and Surgical Treatment of Staphylococcal Pneumonia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A PHYSICIAN NOT OBLIGED TO ANSWER CALL.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1957)

and that the method has no value.More recent experimen- tal work carried out with far more effective hyaluronidase inhibitors, such as rehibin, has shown that, though when added to semen which has then been inseminated it has decreased the fertilizing capacity of the semen, when administered by mouth it has been wholly ineffective.In- deed, since hyaluronidase inhibitors (and other enzyme in-
Pathways for the Mutagenesis of 1-Nitropyrene and Dinitropyrenes in the Human Hepatoma Cell Line HepG2
Authors: Kimberly J. Silvers, E. Priyadarshini Eddy, Elena C. McCoy, Herbert S. Rosenkranz, Paul C. Howard
Journal: Environmental Health Perspectives (1994)

The mutagenicity, metabolism, DNA adduction and induction of unscheduled DNA synthesis (UDS) of 1-nitropyrene and 1,8-dinitropyrene were investigated in the human hepatoma cell line HepG2.Previous results had demonstrated that 1-nitropyrene was both mutagenic at the hgprt locus and induced UDS in these cells.In the present study, we find that the dinitropyrenes, although highly mutagenic in Salmonella typhimurium, are not mutagenic and do not induce UDS in the HepG2.Although the rate of 1,8-dinitropyrene nitroreduction was less than that of 1-nitropyrene nitroreduction, this did not explain the lack of mutagenicity and UDS induction by the dinitropyrenes.Therefore, it is proposed that the arylhydroxylamine O-esterificase is not expressed in these cells.Since cytochrome P450-mediated C-oxidation is the predominant metabolic pathway in vivo, we sought to deter- mine if an increase in the ratio of cytochrome P450-mediated C-oxidation over nitroreduction would result in increased or decreased DNA adducts in the HepG2.The administration of 2.5 pM 3-methylcholanthrene to the HepG2 increased the ratio of C-oxidation/nitroreduction from 2.8 ± 1.9 to 50.4 ± 46.1.This was accompanied by a decrease in the C8-guanyl adduct of 1-nitropyrene (via nitroreduction) from 18.7 ± 7.0 to 4.8 ± 1.7 fmoles/pg DNA, without any further increase in other 1-nitropyrene DNA adducts.These results suggest that the cytochrome P450-mediated metabolism of 1nitropyrene to epoxides, phenols, and dihydrodiols is not an activation pathway in the HepG2 cells, and may explain the weak carcinogenicity of 1- nitropyrene in vivo, where cytochrome P450-mediated C-oxidation predominates.
Abstract 1281: Human Adipose Tissue-derived Stem Cells Potently Preserve Cardiac Function Resulting From Permanently Induced Myocardial Ischemia
Authors: Liying Cai, Brian H Johnstone, Todd G Cook, Keith L March
Journal: Circulation (2007)

Background The use of stem cells has gained much interest as a potential therapeutic approach for repair of damage caused by a variety of cardiac insults. We and others have demonstrated the ability of pluripotent adipose-derived stem cells (ASCs), to promote repair in ischemic skeletal tissues. Here we demonstrate that ASCs also stimulate a robust functional improvement following acute myocardial infarction (MI) in rats. Methods and Results ASCs were harvested from human subcutaneous adipose tissue. ASCs were characterized in vitro before in vivo testing. Growth and metabolic activity of human microvascular endothelial cells (HMVEC) cultured in growth-factor deficient minimal medium (MM) increased 1.7-fold when supplemented with a 1:1 mixture of ASC CM ( p &lt;0.01). Sprout formation by HMVECs and migration of endothelial progenitor cell (EPC) was enhanced by 2.1 and 2.0-fold, repectively, when ASC CM was added to MM ( p &lt;0.01). Following demonstration of potency in vitro, the ASCs were evaluated for the ability to protect and rescue ischemic myocardium in an athymic nude rat following permanent ligation of the proximal LAD region. Immediately after ligation 10 6 ASCs in 100 μl saline or carrier alone was injected into 2 sites of the peri-infarct region, then at 4 and 28 d heart function was evaluated echocardiography using a Visualsonics Vivo770. ASC-treated rats consistently exhibited better cardiac function at 1 month compared to the saline control group. LV ejection fraction of the ASC group was 56 ± 7% (mean ± SEM) vs 37 ± 3% for the control (p&lt;0.04). Fractional shortening was 32 ± 5% (ASC) vs 19 ± 2% (p&lt;0.04). LV volumes both at end-diastolic and end-systolic stages were lower in ASC group (311 ± 17 μl and 139 ± 21 μl, respectively) than saline group (391 ± 30 μl and 249 ± 27 μl) (p&lt;0.03). Anterior wall thinning was attenuated in ASC group (1.6 ± .08 mm vs 1.2 ± .2, at end-diastole, p&lt;0.03). Post-mortem histological analysis demonstrated that ASC treated hearts had lower fibrosis (26 ± 6% vs 34 ± 6%; p&lt;0.05). Conclusion We have demonstrated that ASCs have great potential as a cell therapy to preserve heart function following ischemic insult. Given the abundant source of ASCs, therapies with these cells have a higher potential for widespread adoption compared to more rare cell types.
Treatise on Appendicitis.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lymph Drainage in Patients With Congestive Heart Failure: Comparison With Findings in Hepatic Cirrhosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal